Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Mitry

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2013
Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patientsThomas Aparicio, Jean-Louis Jouve, Laurent Teillet, et al.
Molecular Cancer Therapeutics|October 24, 2015
High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 StudySylvain Manfredi, Olivier Bouché, Philippe Rougier, et al.
The New England Journal of Medicine|June 7, 2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung CancerSolange Peters, D Ross Camidge, Alice T Shaw, et al.
JAMA Oncology|September 1, 2022
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical TrialThierry Conroy, Florence Castan, Anthony Lopez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trialsEmmanuel Mitry, Anthony L A Fields, Harry Bleiberg, et al.
Neuroendocrinology|February 3, 2017
Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)Guillaume Roquin, Eric Baudin, Catherine Lombard-Bohas, et al.
The American Journal of Gastroenterology|September 2, 2008
Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screeningCatherine Julié, Christophe Trésallet, Antoine Brouquet, et al.
Cancer Medicine|May 28, 2018
Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrencesWulfran Cacheux, Petros Tsantoulis, Adrien Briaux, et al.
Cancer Treatment Reviews|March 29, 2025
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?Arthur Géraud, Paul Gougis, Alexandre de Nonneville, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical TrialRémy Nicolle, Jean-Baptiste Bachet, Alexandre Harlé, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2013
Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patientsThomas Aparicio, Jean-Louis Jouve, Laurent Teillet, et al.
Molecular Cancer Therapeutics|October 24, 2015
High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 StudySylvain Manfredi, Olivier Bouché, Philippe Rougier, et al.
The New England Journal of Medicine|June 7, 2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung CancerSolange Peters, D Ross Camidge, Alice T Shaw, et al.
JAMA Oncology|September 1, 2022
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical TrialThierry Conroy, Florence Castan, Anthony Lopez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trialsEmmanuel Mitry, Anthony L A Fields, Harry Bleiberg, et al.
Neuroendocrinology|February 3, 2017
Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)Guillaume Roquin, Eric Baudin, Catherine Lombard-Bohas, et al.
The American Journal of Gastroenterology|September 2, 2008
Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screeningCatherine Julié, Christophe Trésallet, Antoine Brouquet, et al.
Cancer Medicine|May 28, 2018
Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrencesWulfran Cacheux, Petros Tsantoulis, Adrien Briaux, et al.
Cancer Treatment Reviews|March 29, 2025
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?Arthur Géraud, Paul Gougis, Alexandre de Nonneville, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical TrialRémy Nicolle, Jean-Baptiste Bachet, Alexandre Harlé, et al.
Pageof 12